5th Antifibrotic Drug Development Summit (AFDD)

The 5th Antifibrotic Drug Development Summit will provide a unique opportunity to gain cross-discipline actionable insights into how the latest scientific research is being applied to fibrosis pipeline progress. Network with industry pioneers in hot areas of drug development, specifically IPF, NASH, scleroderma, IBD, ILD, CKD, and more to apply disease-specific lessons agnostically, and understand how the industry can achieve the crowning glory of pan-fibrosis antifibrotic drugs.

Unmissable Highlights for 2021:
* Join the active discussion surrounding redefining approvable clinical endpoints with the FDA to enhance opportunities for creative clinical trial design and drive your clinical development
* Engage with early initiatives to establish clinical development programs in IBD-associated fibrosis with Cleveland Clinic to kickstart your intestinal fibrosis pipeline as this grows in interest for biopharma
* Investigate the buzz around reprogramming epithelial cells to promote tissue repair in fibrotic disorders with Genentech to understand new strategies for regenerative medicine and overcome mechanistic bottlenecks
* Gain vital insights from Pfizer on how the industry can revolutionize the translatability of current disease models and collaboratively guide the creation of technologies that can better mimic human physiology
* Embrace more successful clinical trial design with an enhanced focus on patient-reported outcomes with Novartis to identify precision medicine approaches, promote patient engagement, and discuss regulatory barriers to novel endpoints

Speakers: Bernard Allan, Takeda, Bertil Lindmark, Galecto, Bertram Bleck, Takeda, Britta Siegmund, Charite Universitatsmedizin Berlin, Bryan Fuchs, Ferring Pharmaceuticals, Cara Williams, Pfizer, Carmel Nanthakumar, GSK, Craig Conoscenti, Boehringer Ingelheim, David Lagares, Harvard Medical School, Danny Jonigk, Medical School, Dean Welsch, Therapeutics, Deborah Nguyen, Takeda, Elias Papatheodorou, Genkyotex, Elizabeth Redente, Jewish Health, Eric White, Boehringer Ingelheim, Florian Rieder, Cleveland Clinic, Frank Anania, FDA, Henrik Landgren, AbbVie, Joe Arron, Genentech, Joe Garcia, Aqualung Therapeutics, Joe Sarret, CohBar, Johann Gudjonsson, University of Michigan, Kristoffer Ostridge, AstraZeneca, KT Park, Genentech, Liat Hayardeny, Galmed Pharmaceuticals, Lisa Schopf, Pfizer, Majd Mouded, Novartis Institutes for BioMedical Research, Meera Ramanujam, Boehringer Ingelheim, Nobuhiko Kamada, University of Michigan, Orit Rozenblatt- Rosen, Genentech, Paul Noble Chair, Cedars Sinai Medical Center, Peter Schafer, Bristol Myers Squibb, Peter Higgins, University of Michigan, Pnina Fishman, Can Fite BioPharma, Richard Torstenson, AstraZeneca, Robert Lafyatis, University of Pittsburgh, Rohit Batta, Vicore Pharma, Samir Ounzain, HAYA Therapeutics, Tamas Schweighoffer, Alentis Therapeutics

Others Details

URL: Brochure: https://go.evvnt.com/812397-2?pid=6581 Time: 08:25 - 17:00